Shares of the pharmaceutical company, Baudax Bio (NASDAQ: BXRX) surged in morning trading on Tuesday after the company announced positive topline data for BX1000. BX1000 is a neuromuscular blockade (NMB) in patients undergoing elective surgery.
BX1000 underwent a Phase 2 randomized, double-blind, actively-controlled clinical trial. This trial compared three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium administered to 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia. This trial indicated that BX1000 “met the primary endpoint of readiness for intubation (evaluated as ‘Good’ or ‘Excellent’) at all dose levels assessed. No severe adverse events were observed in any dose regimen.”
Even with today’s price rise in BXRX stock, the shares have tanked more than 90% in the past year.
